Scalper1 News
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been leaking out for a couple months now, and the subject was a major, if unnamed, topic of Actavis’ Q3 earnings call last week. However, Bloomberg’s latest report has anonymous sources saying an agreement Scalper1 News
Scalper1 News